[LOGO NEWS RELEASE Skystar Bio-Pharmaceutical Announces Revenue of $20.9 Million For Third Quarter Fiscal Year 2011 Revenues up 12.6%; Net Income up 16.2%; EPS of $1.08 Per Basic and Fully Diluted Share XI’AN, CHINA – November 14, 2011 -- - Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) ("Skystar" or the "Company"), Third Quarter 2011 Highlights · Revenue increases 13% YoY to record $20.9]
[LOGO NEWS RELEASE Skystar Bio-Pharmaceutical Announces Revenue of $20.9 Million For Third Quarter Fiscal Year 2011 Revenues up 12.6%; Net Income up 16.2%; EPS of $1.08 Per Basic and Fully Diluted Share XI’AN, CHINA – November 14, 2011 -- - Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) ("Skystar" or the "Company"), Third Quarter 2011 Highlights · Revenue increases 13% YoY to record $20.9]
[LOGO NEWS RELEASEystar Bio-Pharmaceutical Announces Revenue of $20.9 Million For Third Quarter Fiscal Year 2011 Revenues up 12.6%; Netome up 16.2%; EPS of $1.08 Per Basic and Fully Diluted Share XIAN, CHINA November 14, 2011 -- -ystar Bio-Pharmaceuticalmpany (NASDAQ:SKBI) ("Skystar" or the "Company"), Third Quarter 2011 Highlights]
[LOGO NEWS RELEASEystar Bio-Pharmaceutical Announces Revenue of $20.9 Million For Third Quarter Fiscal Year 2011 Revenues up 12.6%; Netome up 16.2%; EPS of $1.08 Per Basic and Fully Diluted Share XIAN, CHINA November 14, 2011 -- -ystar Bio-Pharmaceuticalmpany (NASDAQ:SKBI) ("Skystar" or the "Company"), Third Quarter 2011 Highlights]
[SKYSTAR BIO-PHARMACEUTICAL COMPANY FORM 10-Q INDEX Page No. 3 PART I. FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements 4 Condensed Consolidated Balance Sheets as of September 30, 2011 (unaudited) and December 31, 2010 F-1 Condensed Consolidated Statements of Income and Other Comprehensive Income for the Three and Nine Months Ended September 30, 2011 and 2010 (unaudited) F-2 Condensed Consolidated] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Weibing Lu, certify that: 1. I have reviewed this quarterly report on Form 10-Q of SKYSTAR BIO-PHARMACEUTICAL COMPANY; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Bing Mei, certify that: 1. I have reviewed this quarterly report on Form 10-Q of SKYSTAR BIO-PHARMACEUTICAL COMPANY; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. Weibing Lu Chief Executive Officer November 14, 2011] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. Bing Mei Chief Financial Officer November 14, 2011]
[SKYSTAR BIO-PHARMACEUTICAL COMPANY FORM 10-Q INDEX Page No. 3 PART I. FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements 4 Condensed Consolidated Balance Sheets as of September 30, 2011 (unaudited) and December 31, 2010 F-1 Condensed Consolidated Statements of Income and Other Comprehensive Income for the Three and Nine Months Ended September 30, 2011 and 2010 (unaudited) F-2 Condensed Consolidated] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Weibing Lu, certify that: 1. I have reviewed this quarterly report on Form 10-Q of SKYSTAR BIO-PHARMACEUTICAL COMPANY; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Bing Mei, certify that: 1. I have reviewed this quarterly report on Form 10-Q of SKYSTAR BIO-PHARMACEUTICAL COMPANY; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. Weibing Lu Chief Executive Officer November 14, 2011] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. Bing Mei Chief Financial Officer November 14, 2011]
[SKYSTAR BIO-PHARMACEUTICALMPANY FORM10-Q INDEX PageNo. 3 PART I.FINANCIAL INFORMATION Item 1.ndensednsolidated Financial Statements 4ndensednsolidated Balance Sheets of September 30, 2011 (unaudited) and December 31, 2010 F-1ndensednsolidated Statements ofome and Othermprehensiveomefor the Three and Nine Months Ended September 30, 2011 and 2010 (unaudited)] [SECTION 302 OF THERBANES-OXLEY ACT OF 2002 I, WeibingLu, certify that: 1. I have reviewed this quarterly report on Form 10-Q ofYSTARBIO-PHARMACEUTICALCOMPANY; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the] [SECTION 302 OF THERBANES-OXLEY ACT OF 2002 I, Bing Mei, certify that: 1. I have reviewed this quarterly report on Form 10-Q ofYSTARBIO-PHARMACEUTICALCOMPANY; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and result of operations of thempany at thetes and for the periods indicated. WeibingLu Chief Executive Officer November 14, 2011 v240211_ex32-1.htm] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and result of operations of thempany at thetes and for the periods indicated. Bing Mei Chief Financial Officer November 14, 2011]
[SKYSTAR BIO-PHARMACEUTICALMPANY FORM10-Q INDEX PageNo. 3 PART I.FINANCIAL INFORMATION Item 1.ndensednsolidated Financial Statements 4ndensednsolidated Balance Sheets of September 30, 2011 (unaudited) and December 31, 2010 F-1ndensednsolidated Statements ofome and Othermprehensiveomefor the Three and Nine Months Ended September 30, 2011 and 2010 (unaudited)] [SECTION 302 OF THERBANES-OXLEY ACT OF 2002 I, WeibingLu, certify that: 1. I have reviewed this quarterly report on Form 10-Q ofYSTARBIO-PHARMACEUTICALCOMPANY; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the] [SECTION 302 OF THERBANES-OXLEY ACT OF 2002 I, Bing Mei, certify that: 1. I have reviewed this quarterly report on Form 10-Q ofYSTARBIO-PHARMACEUTICALCOMPANY; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and result of operations of thempany at thetes and for the periods indicated. WeibingLu Chief Executive Officer November 14, 2011 v240211_ex32-1.htm] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and result of operations of thempany at thetes and for the periods indicated. Bing Mei Chief Financial Officer November 14, 2011]
[Explanatory Note This Form 10-Q/A should be read innjunction with the original Form 10-Q, whichntinues toeak of thete of the Form 10-Q. Exceptecifically notedove, this Form 10-Q/A does not modify or update disclosures in the original Form 10-Q. Accordingly, this Form 10-Q/A does not reflect events occurring after the filing of the Form 10-Q or]
[NEWS RELEASE Skystar Bio-Pharmaceutical Reports Second Quarter 2011 Results $9.1 Million Top Line; $0.21 Diluted EPS; Expanded Direct Distribution and Sales Channels XI’AN, CHINA – August 23, 2011 -- - Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) ("Skystar" or the "Company"), Second Quarter 2011 Highlights · Revenue increases 10% YoY to $9.1 million · Veterinary vaccines totaled $0.4million, up 1.2% YoY · Veterinary]
